<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04633707</url>
  </required_header>
  <id_info>
    <org_study_id>Guangzhou Brain Hospital BLT</org_study_id>
    <nct_id>NCT04633707</nct_id>
  </id_info>
  <brief_title>Adjunctive Bright Light Therapy for Patients With Depression</brief_title>
  <official_title>Adjunctive Bright Light Therapy for Patients With Depression at Different Time Period: A Randomized Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangzhou Psychiatric Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Psychiatric Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study would enroll depressed adolescents and adults with bipolar I or II disorder or&#xD;
      major depressive disorder who are receiving stable psychiatric medication (excluding patients&#xD;
      with hypomania or mania, mixed symptoms, or rapid cycling). Participants would be randomly&#xD;
      assigned to treatment with either 1,0000-lux bright white light therapy in the morning or&#xD;
      1,0000-lux bright white light therapy in the afternoon, or &lt;100-lux dim red placebo light&#xD;
      therapy in the afternoon (N=59 for each group). Participants would be treated for 6 weeks.&#xD;
      Symptoms would be assessed every two weeks with the 24-items Hamilton Depression Scale, the&#xD;
      Young Mania Rating Scale, and the Pittsburgh Sleep Quality Index; salivary melatonin and&#xD;
      cortisol concentrations will be also measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators would divide the participants enrolled into three groups: adjunctive&#xD;
      morning bright light therapy (BLT) group (light intensity: 10000lux, color: white light,&#xD;
      duration of each intervention session: 30min, time period of intervention: 7:00~9:00 a.m.),&#xD;
      adjunctive afternoon BLT group (light intensity: 10000lux, color: white light, duration of&#xD;
      each intervention session: 30min, time period of intervention: 12:00~14:00 p.m.), adjunctive&#xD;
      placebo therapy group (light intensity: &lt;100lux, color: dark red, duration of each&#xD;
      intervention session: 30min, time period of intervention: 12:00~14:00 p.m.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>up to week 6</time_frame>
    <description>Participants with a decrease in 24-items Hamilton Depression Scale (HDRS) score of 50% or more from baseline. HDRS is used to measure the depressive severity；its measured time range is within the past week. In this study, version of 24-items is used. The patients are depressed when the total score are greater than 19 points, and there are no depression when the total scores are less than points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>manic/hypomanic conversion rate</measure>
    <time_frame>week 2; week 4; week 6</time_frame>
    <description>The Young Mania Rating Scale (YMRS) is used to assess manic/hypomanic symptoms and their severity; its measured time range is within the past week. The higher the score, the more severe the symptom. If the total score is greater than or equal to 20, manic episode is considered; if the total score is less than 6, it means there is no manic/hypomanic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>side effect</measure>
    <time_frame>week 2; week 4;week 6</time_frame>
    <description>record the possible adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sleep quality</measure>
    <time_frame>week 2; week 4;week 6</time_frame>
    <description>Pittsburgh Sleep Quality Index (PSQI) is used to evaluate sleep quality for last month. It's made of 7 items; every item is scored 1-4 point. Total score is obtained by adding up the points of 7 items. Total score range is 0~21 point. The sleep quality is worse when the total score is higher.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Depressive Disorder</condition>
  <condition>Light Therapy</condition>
  <arm_group>
    <arm_group_label>Adjunctive morning BLT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treat participants with adjunctive BLT in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjunctive afternoon BLT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treat participants with adjunctive BLT in the afternoon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjunctive placebo therapy group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>treat participants with adjunctive dim red light in the afternoon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>adjunctive bright white light therapy in the morning</intervention_name>
    <description>the participants would receive adjunctive bright white light therapy in the morning (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 7:00~9:00) for 6 weeks.</description>
    <arm_group_label>Adjunctive morning BLT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>adjunctive bright white light therapy in the afternoon</intervention_name>
    <description>the participants would receive adjunctive bright white light therapy in the afternoon (light intensity: 10000lux, color: white light, duration of each intervention session: 30min, time period: 12:00~14:00) for 6 weeks.</description>
    <arm_group_label>Adjunctive afternoon BLT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>adjunctive dim red light therapy in the afternoon</intervention_name>
    <description>the participants received dim red light therapy (light intensity: &lt;100lux, color: dark red, duration of each intervention session: 30min, time period: 12:00~14:00) for 6 weeks.</description>
    <arm_group_label>Adjunctive placebo therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  12-75 years old&#xD;
&#xD;
          -  Diagnosed using DSM-5 criteria based on the Structured Clinical Interview for Patient&#xD;
             Edition (SCID-P) for adults or Schedule for Affective Disorders and Schizophrenia for&#xD;
             School-Age Children-Present and Lifetime version (Kiddie-SADS-PL) for adolescents for&#xD;
             the diagnosis of bipolar I or II disorder or major depressive disorder&#xD;
&#xD;
          -  24-items Hamilton Depression Rating Scale score ≥ 20, Young Mania Rating Scale score &lt;&#xD;
             6&#xD;
&#xD;
          -  Participants with bipolar disorder taking at least one mood stabilizer, and the types&#xD;
             of drugs have not changed in one week;&#xD;
&#xD;
          -  Antidepressants can be taken, and the types of antidepressants have not changed in one&#xD;
             week&#xD;
&#xD;
          -  Low-dose benzodiazepines can be used, with a maximum of 2 mg of lorazepam equivalent&#xD;
             per day&#xD;
&#xD;
          -  Right-handed&#xD;
&#xD;
          -  Primary school education or above&#xD;
&#xD;
          -  Sign informed consents after a full explanation of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of brain organic disease or severe traumatic brain injury and severe&#xD;
             physical disease;&#xD;
&#xD;
          -  Drug, alcohol or other psychoactive substance abusers&#xD;
&#xD;
          -  Severe suicide risk;&#xD;
&#xD;
          -  Received modified electric convulsion therapy (MECT) in the past three months&#xD;
&#xD;
          -  Comorbid with ophthalmic diseases (cataract, macular degeneration, glaucoma, retinitis&#xD;
             pigmentosa, etc.) and diseases affecting the retina (retinopathy, diabetes, herpes,&#xD;
             etc.)&#xD;
&#xD;
          -  Taking photosensitive drugs (phenothiazines, antimalarials, propranolol, melatonin,&#xD;
             hypericum, stimulants or NSAIDs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Kangguang, MD;PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangzhou Psychiatric Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Kangguang, MD;PHD</last_name>
    <phone>13560360144</phone>
    <phone_ext>18028619981</phone_ext>
    <email>linkangguang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liu Tao, MD</last_name>
    <phone>15017554527</phone>
    <email>liutaolp@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangzhou Brain Hospital (Guangzhou Huiai Hospital)</name>
      <address>
        <city>Guanzhou</city>
        <state>Guangdong</state>
        <zip>510370</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>March 21, 2021</last_update_submitted>
  <last_update_submitted_qc>March 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Psychiatric Hospital</investigator_affiliation>
    <investigator_full_name>Kangguang Lin</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Bright Light Therapy</keyword>
  <keyword>Time Period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

